Lai K N, Lo W K
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam.
Perit Dial Int. 1999;19 Suppl 3:S26-31; discussion S32-4.
The socioeconomic statuses of Asian countries are diverse and government reimbursement policies for renal replacement programs vary greatly from one country to another. Both factors affect not only the availability of treatment but also the choice of dialysis modality. Despite the economic growth of Hong Kong over the past three decades, the resources spent by our government on health services are less than other developed countries. The National Health Service, which is run on a tight budget, supports almost 95% of the patients on renal replacement programs. Due to the cost-effectiveness and reimbursement from the government, 79% of patients with end-stage renal failure in Hong Kong are treated with continuous ambulatory peritoneal dialysis (CAPD). All new patients entering the renal replacement program run by the National Health Service are offered CAPD as the first-line dialytic treatment. Due to budgetary constraint, over the past 10 years dialysis centers in Hong Kong have adopted a small-volume regime of 3 x 2-L daily exchanges as the initial dialysis prescription. This dialysis prescription will be considered to be suboptimal by Western standards, but the survival of these patients was comparable to, or even better than, other areas despite a lower Kt/V. These preliminary studies suggest small-volume dialysis may be an acceptable compromise in Asian populations with their smaller body size, given the financial constraints. These issues are especially important in Asia, where financial resources for renal replacement therapy are still limited in most countries and many patients have to continue working to pay for their renal replacement treatment. Using this small-volume dialytic regime, more patients may be treated with the limited financial resources. Furthermore, our experience raises the question of the importance of nutritional status in patient survival.
亚洲国家的社会经济状况各不相同,各国政府对肾脏替代治疗项目的报销政策也存在很大差异。这两个因素不仅影响治疗的可及性,还影响透析方式的选择。尽管香港在过去三十年中经济有所增长,但政府在医疗服务上的支出仍低于其他发达国家。预算紧张的国民保健服务体系为近95%接受肾脏替代治疗项目的患者提供支持。由于成本效益和政府报销,香港79%的终末期肾衰竭患者接受持续性非卧床腹膜透析(CAPD)治疗。所有进入国民保健服务体系肾脏替代治疗项目的新患者都被提供CAPD作为一线透析治疗。由于预算限制,在过去十年中,香港的透析中心采用了每日3次、每次2升的小剂量透析方案作为初始透析处方。按照西方标准,这种透析处方可能被认为不够理想,但尽管Kt/V较低,这些患者的生存率与其他地区相当,甚至更高。这些初步研究表明,鉴于经济限制,对于体型较小的亚洲人群,小剂量透析可能是一种可接受的折衷方案。这些问题在亚洲尤为重要,因为在大多数国家,肾脏替代治疗的财政资源仍然有限,许多患者不得不继续工作以支付肾脏替代治疗费用。采用这种小剂量透析方案,可以用有限的财政资源治疗更多患者。此外,我们的经验提出了营养状况对患者生存重要性的问题。